- Article metrics
- Last updated: Fri, 10 Oct 2025 7:32:20 Z
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study
Access & Citations
-
- 7790
- Article Accesses
-
- 30
- Citations
Citation counts are provided by Dimensions and depend on their data availability. Counts will update daily, once available.
